Susquehanna Portfolio Strategies »

Black Diamond Therapeutics shares owned by Susquehanna Portfolio Strategies

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Susquehanna Portfolio Strategies from 13F filings

Historical chart of Susquehanna Portfolio Strategies investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Susquehanna Portfolio Strategies consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Susquehanna Portfolio Strategies

Quarter filed Position value Share count Share price at filing
2025-09-30 $800k 211k 3.79
2025-06-30 $142k 57k 2.48

More positions owned by Susquehanna Portfolio Strategies

Oracle Corporation (ORCL)
Apple (AAPL)
Blackrock (BLK)
Merck & Co (MRK)
Arista Networks Com Shs (ANET)
Pfizer (PFE)
Amazon (AMZN)
Simon Property (SPG)
Baker Hughes Company Cl A (BKR)
Realty Income (O)
American Express Company (AXP)
Chipotle Mexican Grill (CMG)
Vulcan Materials Company (VMC)
General Motors Company (GM)
MetLife (MET)

View all positions for Susquehanna Portfolio Strategies

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
Vestal Point Capital
NEA Management Company
Vanguard Group
Tang Capital Management
Marshall Wace
Siren
BlackRock
Arrowstreet Capital, Limited Partnership
Millennium Management
UBS Group
AWM Investment Company
Renaissance Technologies
Geode Capital Management
Northern Trust

View all funds holding Black Diamond Therapeutics